

AREA OF THERAPY	PRECLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL RIGHTS
HEMATOLOGIC MALIGNANCIES					
Multiple Myeloma Relapsed/refractory BOSTON	SELINEXOR + VELCADE ¹				
Penta-refractory STORM	SELINEXOR ²				
Relapsed/refractory STOMP	SELINEXOR + BACKBONE THERAPIES ³				
Diffuse Large B-cell Lymphoma SADAL	SELINEXOR				
SOLID TUMOR MALIGNANCIES					
Liposarcoma SEAL	SELINEXOR				
Endometrial Cancer SIENDO ⁴	SELINEXOR				
Glioblastoma KING	SELINEXOR				
ADDITIONAL ONCOLOGY PROGRAMS					
MDS, CRC, PrC	ELTANEXOR (KPT-8602)				
Solid Tumors & Lymphoma	KPT-9274				
OTHER INDICATIONS					
Lymphoma in Companion Animals	VERDINEXOR (KPT-335)				



1 Oral selinexor, Velcade® (bortezomib) and dexamethasone vs. Velcade and dexamethasone

2 Oral selinexor + dexamethasone

3 Oral selinexor and dexamethasone + Revlimid® (lenalidomide), Pomalyst® (pomalidomide), Velcade, Kyprolis® (carfilzomib) or Darzalex® (daratumumab)

4 Investigator-sponsored randomized Phase III trial

Territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN countries
 **Anive holds exclusive worldwide rights to research, develop and commercialize verdinexor only for the treatment of cancer in companion animals